脓毒症患者高乳酸血症的死亡率高于难治性低血压
该研究为ARISE试验的二次分析,纳入1332例脓毒症患者,其中478例(35.9%)为单纯高乳酸血症,854例(64.1%)为单纯难治性低血压。采用倾向评分加权分析显示,单纯高乳酸血症组90天死亡风险是单纯难治性低血压组的1.7倍(95%CI 1.2-2.5,P=0.003),且存活出院率更低(ICU亚风险比0.77,95%CI 0.64-0.92;医院亚风险比0.79,95%CI 0.66-0.95)。作者认为,在脓毒症患者中,单纯高乳酸血症可能比单纯难治性低血压提示更高的疾病严重程度和更差预后。
要点
- 在脓毒症患者中,单纯高乳酸血症(乳酸≥4 mmol/L不伴难治性低血压)的90天死亡风险是单纯难治性低血压(对≥1000 mL液体复苏无反应)的1.7倍(倾向加权风险比95%CI 1.2-2.5,P=0.003)。
- 单纯高乳酸血症组基线APACHE II评分更高(16.2±6.4 vs 14.5±6.4,P<0.001),提示病情更重。
- 单纯高乳酸血症组存活出院率更低:ICU出院倾向加权亚风险比0.77(95%CI 0.64-0.92,P<0.005),医院出院亚风险比0.79(95%CI 0.66-0.95,P=0.01)。
- 两组年龄和感染来源相似,但单纯高乳酸血症患者90天死亡率更高,提示单纯高乳酸血症可能定义更高的疾病严重程度。
适用人群与场景
- ARISE试验中脓毒症患者,表现为单纯高乳酸血症(乳酸≥4 mmol/L不伴难治性低血压)或单纯难治性低血压(对≥1000 mL液体复苏无反应)。
诊断标准与关键阈值
- 单纯高乳酸血症:乳酸≥4 mmol/L且无难治性低血压。
- 单纯难治性低血压:对≥1000 mL液体复苏无反应的低血压,且不伴高乳酸血症。
研究设计与关键结果
- 研究类型:ARISE试验的二次分析,纳入1332例脓毒症患者,其中单纯高乳酸血症478例(35.9%),单纯难治性低血压854例(64.1%)。
- 主要终点:90天全因死亡风险,单纯高乳酸血症组是单纯难治性低血压组的1.7倍(倾向加权风险比95%CI 1.2-2.5,P=0.003)。
- 关键次要终点:ICU存活出院倾向加权亚风险比0.77(95%CI 0.64-0.92,P<0.005),医院存活出院亚风险比0.79(95%CI 0.66-0.95,P=0.01),单纯高乳酸血症组均更低。
- 基线特征:单纯高乳酸血症组APACHE II评分16.2±6.4,单纯难治性低血压组14.5±6.4,P<0.001;年龄中位数分别为66.2(54.2-76.3)岁和65.2(50.9-75.5)岁。
证据类型、等级与局限
- 证据类型:ARISE试验的二次分析(队列研究)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在脓毒症患者中,单纯高乳酸血症可能定义更高的疾病严重程度和更差预后,提示对这类患者应给予更多关注。
指南或共识出处
- ARISE试验(Australian Resuscitation in Sepsis Evaluation)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In septic patients, it is uncertain whether isolated hyperlactatemia (lactate ≥4 mmol/L without refractory hypotension) can be used to diagnose septic shock and whether mortality rate differs from that of isolated refractory hypotension (refractory to 1000 mL or greater fluid bolus).
AIMS: To compare baseline characteristics, treatments, and outcomes of participants enrolled into the Australian Resuscitation in Sepsis Evaluation (ARISE) trial according to the presence of isolated hyperlactatemia or isolated refractory hypotension.
PATIENTS: Cohort of 1,332 ARISE participants with sepsis and either isolated hyperlactatemia or isolated refractory hypotension.
METHODS: We performed a secondary analysis of the ARISE data, constructing a propensity score model to discriminate between hyperlactatemia and isolated refractory hypotension. We analyzed 90-day all-cause mortality using a generalized linear model and inverse propensity score weighting. We modeled length of intensive care unit (ICU) and hospital stay using time to event analyses incorporating mortality as a competing risk.
RESULTS: There were 478 participants (35.9%) with isolated hyperlactatemia and 854 (64.1%) with isolated refractory hypotension. They had similar median (interquartile range) ages (66.2 [54.2, 76.3] years vs. 65.2 [50.9, 75.5] years) and similar sources of infection. However, isolated hyperlactatemia participants had higher mean (standard deviation) baseline APACHE II scores (isolated hyperlactatemia 16.2 [6.4]) vs. 14.5 [6.4] for isolated refractory hypotension; P < 0.001). Isolated hyperlactatemia participants had a 1.7 times higher risk of 90-day mortality (propensity-weighted risk ratio; 95% confidence intervals [CI] 1.2, 2.5, P = 0.003). They were less likely to be discharged alive from ICU and hospital (propensity weighted sub-hazard ratio 0.77 (95% CI 0.64, 0.92; P < 0.005) and 0.79 (95% CI 0.66, 0.95; P = 0.01), respectively).
CONCLUSIONS: ARISE trial participants with isolated hyperlactatemia had worse adjusted 90-day mortality than those with isolated refractory hypotension. In septic patients, isolated hyperlactatemia may define greater illness severity and worse outcomes than isolated refractory hypotension.
参考来源
- Gotmaker R, Peake SL, Forbes A, et al. Mortality is Greater in Septic Patients With Hyperlactatemia Than With Refractory Hypotension. Shock. 2017. PMID: 28248722. doi:10.1097/SHK.0000000000000861
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。